Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RHEB | Q15382 | 4/20 | 0.52 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876215 | 0.84 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL22955432 | 0.82 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL7515773 | 0.81 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL27762363 | 0.80 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL30615082 | 0.73 | RHEB (0.73) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL9000174 | 0.73 | RHEB (0.73) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL3732815 | 0.73 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL22956060 | 0.72 | GUSB (0.53) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL10333320 | 0.72 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL7520681 | 0.71 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | NPC1 2550/4885RAB9A 4532/4885MEN1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.